Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Phyllis Yale | F | 66 | 5 years | |
Derica Rice | M | 59 | 4 years | |
Paula Price | F | 62 | 4 years | |
Theodore Samuels | M | 69 | 7 years | |
David Elkins | M | 55 | 5 years | |
Mark Rolfe | M | - | 5 years | |
Julia Haller | M | 69 | 5 years | |
Karen Vousden | M | 66 | 6 years | |
Teresa Foy | M | 60 | 5 years | |
Leslie Waltke | F | - | 12 years | |
Nina Goworek | F | - | 6 years | |
Samit Hirawat | M | 55 | 5 years | |
Robert Plenge | M | 53 | 5 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Lamberto Andreotti | M | 73 | 19 years | |
Nancy Wysenski | F | 66 |
EMD Pharmaceuticals, Inc.
EMD Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Part of Merck KGaA, EMD Pharmaceuticals, Inc. is a private company that manufactures pharmaceutical preparations. The company is based in Durham, NC. The company was founded by Nancy J. Wysenski. | 7 years |
Graham Hetherington | M | 65 | 6 years | |
Angus Russell | M | 68 |
Shire Plc /Old/
Shire Plc /Old/ Miscellaneous Commercial ServicesCommercial Services Shire is a global specialty pharmaceutical company marketing products to defined customer groups (specialist doctors). Sales and marketing is a core Shire competence. Shire combines investment in product development with careful attention to risk management. Shire currently focuses on three therapeutic areas - central nervous system disorders (CNS), gastrointestinal (GI) and renal diseases. Shire has particular expertise in ADHD as a result of its development and marketing of the leading brand in the US market, ADDERALL and the new once a day version, ADDERALL XR. The group has a sales and marketing infrastructure with a broad portfolio of products targeting the US, Canada, UK, Republic of Ireland, France, Germany, Italy and Spain. Shire covers other significant pharmaceutical markets indirectly through distributors. They have already appointed such distributors including, Australia, Denmark, Finland, Hong Kong, Israel, Malaysia, Norway, Philippines, Singapore, South Africa, South Korea and Thailand. It is founded in 1986 | 14 years |
James Bowling | M | 56 | 10 years | |
Rainer Lichtenberger | M | 65 | 14 years | |
Susan Kilsby | F | 65 | 8 years | |
Thomas Lynch | M | 63 | 5 years | |
David John Kappler | M | 76 |
Shire Plc /Old/
Shire Plc /Old/ Miscellaneous Commercial ServicesCommercial Services Shire is a global specialty pharmaceutical company marketing products to defined customer groups (specialist doctors). Sales and marketing is a core Shire competence. Shire combines investment in product development with careful attention to risk management. Shire currently focuses on three therapeutic areas - central nervous system disorders (CNS), gastrointestinal (GI) and renal diseases. Shire has particular expertise in ADHD as a result of its development and marketing of the leading brand in the US market, ADDERALL and the new once a day version, ADDERALL XR. The group has a sales and marketing infrastructure with a broad portfolio of products targeting the US, Canada, UK, Republic of Ireland, France, Germany, Italy and Spain. Shire covers other significant pharmaceutical markets indirectly through distributors. They have already appointed such distributors including, Australia, Denmark, Finland, Hong Kong, Israel, Malaysia, Norway, Philippines, Singapore, South Africa, South Korea and Thailand. It is founded in 1986 | 12 years |
Ludovic Robin | M | - | 8 years | |
Tatjana Anni Hilde May | F | 58 |
Shire Plc /Old/
Shire Plc /Old/ Miscellaneous Commercial ServicesCommercial Services Shire is a global specialty pharmaceutical company marketing products to defined customer groups (specialist doctors). Sales and marketing is a core Shire competence. Shire combines investment in product development with careful attention to risk management. Shire currently focuses on three therapeutic areas - central nervous system disorders (CNS), gastrointestinal (GI) and renal diseases. Shire has particular expertise in ADHD as a result of its development and marketing of the leading brand in the US market, ADDERALL and the new once a day version, ADDERALL XR. The group has a sales and marketing infrastructure with a broad portfolio of products targeting the US, Canada, UK, Republic of Ireland, France, Germany, Italy and Spain. Shire covers other significant pharmaceutical markets indirectly through distributors. They have already appointed such distributors including, Australia, Denmark, Finland, Hong Kong, Israel, Malaysia, Norway, Philippines, Singapore, South Africa, South Korea and Thailand. It is founded in 1986 | 7 years |
Ian Karp | M | - | 5 years | |
Kathleen Anne Nealon | F | 70 |
Shire Plc /Old/
Shire Plc /Old/ Miscellaneous Commercial ServicesCommercial Services Shire is a global specialty pharmaceutical company marketing products to defined customer groups (specialist doctors). Sales and marketing is a core Shire competence. Shire combines investment in product development with careful attention to risk management. Shire currently focuses on three therapeutic areas - central nervous system disorders (CNS), gastrointestinal (GI) and renal diseases. Shire has particular expertise in ADHD as a result of its development and marketing of the leading brand in the US market, ADDERALL and the new once a day version, ADDERALL XR. The group has a sales and marketing infrastructure with a broad portfolio of products targeting the US, Canada, UK, Republic of Ireland, France, Germany, Italy and Spain. Shire covers other significant pharmaceutical markets indirectly through distributors. They have already appointed such distributors including, Australia, Denmark, Finland, Hong Kong, Israel, Malaysia, Norway, Philippines, Singapore, South Africa, South Korea and Thailand. It is founded in 1986 | 4 years |
Anne Minto | F | 70 | 8 years | |
Michael Rosenblatt | M | 76 |
Shire Plc /Old/
Shire Plc /Old/ Miscellaneous Commercial ServicesCommercial Services Shire is a global specialty pharmaceutical company marketing products to defined customer groups (specialist doctors). Sales and marketing is a core Shire competence. Shire combines investment in product development with careful attention to risk management. Shire currently focuses on three therapeutic areas - central nervous system disorders (CNS), gastrointestinal (GI) and renal diseases. Shire has particular expertise in ADHD as a result of its development and marketing of the leading brand in the US market, ADDERALL and the new once a day version, ADDERALL XR. The group has a sales and marketing infrastructure with a broad portfolio of products targeting the US, Canada, UK, Republic of Ireland, France, Germany, Italy and Spain. Shire covers other significant pharmaceutical markets indirectly through distributors. They have already appointed such distributors including, Australia, Denmark, Finland, Hong Kong, Israel, Malaysia, Norway, Philippines, Singapore, South Africa, South Korea and Thailand. It is founded in 1986 | 1 years |
Flemming Ørnskov | M | 66 | 6 years | |
John E. Elicker | M | 64 | 20 years | |
Carl Decicco | M | 62 | 10 years | |
José Baselga | M | 65 | - | |
Charles Bancroft | M | 65 | 36 years | |
David R. Ginsburg | M | 71 | 8 years | |
Rick Ryan | M | - | 11 years | |
Dominic Blakemore | M | 54 | 4 years | |
Fouad Namouni | M | 55 | 21 years | |
Togo Dennis West | M | 81 | 10 years | |
Barbara H. Deptula | F | 69 |
Shire Plc /Old/
Shire Plc /Old/ Miscellaneous Commercial ServicesCommercial Services Shire is a global specialty pharmaceutical company marketing products to defined customer groups (specialist doctors). Sales and marketing is a core Shire competence. Shire combines investment in product development with careful attention to risk management. Shire currently focuses on three therapeutic areas - central nervous system disorders (CNS), gastrointestinal (GI) and renal diseases. Shire has particular expertise in ADHD as a result of its development and marketing of the leading brand in the US market, ADDERALL and the new once a day version, ADDERALL XR. The group has a sales and marketing infrastructure with a broad portfolio of products targeting the US, Canada, UK, Republic of Ireland, France, Germany, Italy and Spain. Shire covers other significant pharmaceutical markets indirectly through distributors. They have already appointed such distributors including, Australia, Denmark, Finland, Hong Kong, Israel, Malaysia, Norway, Philippines, Singapore, South Africa, South Korea and Thailand. It is founded in 1986 | 8 years |
Michael Bonney | M | 65 | 2 years | |
John F. Niblack | M | 85 | - | |
Jon Stonehouse | M | 63 |
EMD Pharmaceuticals, Inc.
EMD Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Part of Merck KGaA, EMD Pharmaceuticals, Inc. is a private company that manufactures pharmaceutical preparations. The company is based in Durham, NC. The company was founded by Nancy J. Wysenski. | 4 years |
Jeffrey Jones | M | 53 | 5 years | |
Jeffrey Leiden | M | 68 |
Shire Plc /Old/
Shire Plc /Old/ Miscellaneous Commercial ServicesCommercial Services Shire is a global specialty pharmaceutical company marketing products to defined customer groups (specialist doctors). Sales and marketing is a core Shire competence. Shire combines investment in product development with careful attention to risk management. Shire currently focuses on three therapeutic areas - central nervous system disorders (CNS), gastrointestinal (GI) and renal diseases. Shire has particular expertise in ADHD as a result of its development and marketing of the leading brand in the US market, ADDERALL and the new once a day version, ADDERALL XR. The group has a sales and marketing infrastructure with a broad portfolio of products targeting the US, Canada, UK, Republic of Ireland, France, Germany, Italy and Spain. Shire covers other significant pharmaceutical markets indirectly through distributors. They have already appointed such distributors including, Australia, Denmark, Finland, Hong Kong, Israel, Malaysia, Norway, Philippines, Singapore, South Africa, South Korea and Thailand. It is founded in 1986 | 6 years |
Michael Grobstein | M | 81 | 13 years | |
Alan J. Lacy | M | 70 | 12 years | |
Dinesh C. Paliwal | M | 67 | 8 years | |
Laurie Glimcher | M | 72 | 20 years | |
William Burns | M | 76 | 8 years | |
Vicki Sato | M | 75 | 15 years | |
Anita Graham | F | 52 |
Shire Plc /Old/
Shire Plc /Old/ Miscellaneous Commercial ServicesCommercial Services Shire is a global specialty pharmaceutical company marketing products to defined customer groups (specialist doctors). Sales and marketing is a core Shire competence. Shire combines investment in product development with careful attention to risk management. Shire currently focuses on three therapeutic areas - central nervous system disorders (CNS), gastrointestinal (GI) and renal diseases. Shire has particular expertise in ADHD as a result of its development and marketing of the leading brand in the US market, ADDERALL and the new once a day version, ADDERALL XR. The group has a sales and marketing infrastructure with a broad portfolio of products targeting the US, Canada, UK, Republic of Ireland, France, Germany, Italy and Spain. Shire covers other significant pharmaceutical markets indirectly through distributors. They have already appointed such distributors including, Australia, Denmark, Finland, Hong Kong, Israel, Malaysia, Norway, Philippines, Singapore, South Africa, South Korea and Thailand. It is founded in 1986 | 4 years |
Steven Gillis | M | 71 | 7 years | |
David Stout | M | 69 | 6 years | |
Barry James Price | M | 80 |
Shire Plc /Old/
Shire Plc /Old/ Miscellaneous Commercial ServicesCommercial Services Shire is a global specialty pharmaceutical company marketing products to defined customer groups (specialist doctors). Sales and marketing is a core Shire competence. Shire combines investment in product development with careful attention to risk management. Shire currently focuses on three therapeutic areas - central nervous system disorders (CNS), gastrointestinal (GI) and renal diseases. Shire has particular expertise in ADHD as a result of its development and marketing of the leading brand in the US market, ADDERALL and the new once a day version, ADDERALL XR. The group has a sales and marketing infrastructure with a broad portfolio of products targeting the US, Canada, UK, Republic of Ireland, France, Germany, Italy and Spain. Shire covers other significant pharmaceutical markets indirectly through distributors. They have already appointed such distributors including, Australia, Denmark, Finland, Hong Kong, Israel, Malaysia, Norway, Philippines, Singapore, South Africa, South Korea and Thailand. It is founded in 1986 | 14 years |
Patrick J. Langlois | M | 78 |
Shire Plc /Old/
Shire Plc /Old/ Miscellaneous Commercial ServicesCommercial Services Shire is a global specialty pharmaceutical company marketing products to defined customer groups (specialist doctors). Sales and marketing is a core Shire competence. Shire combines investment in product development with careful attention to risk management. Shire currently focuses on three therapeutic areas - central nervous system disorders (CNS), gastrointestinal (GI) and renal diseases. Shire has particular expertise in ADHD as a result of its development and marketing of the leading brand in the US market, ADDERALL and the new once a day version, ADDERALL XR. The group has a sales and marketing infrastructure with a broad portfolio of products targeting the US, Canada, UK, Republic of Ireland, France, Germany, Italy and Spain. Shire covers other significant pharmaceutical markets indirectly through distributors. They have already appointed such distributors including, Australia, Denmark, Finland, Hong Kong, Israel, Malaysia, Norway, Philippines, Singapore, South Africa, South Korea and Thailand. It is founded in 1986 | 6 years |
Robert Bertolini | M | 61 | 4 years | |
Joshua Reed | M | 51 | 2 years | |
Edward Atkinson | M | 58 | 8 years | |
Daniel O’Connell | M | 44 | - | |
Dale Kummerle | M | - | 17 years | |
David Feltquate | M | - | 3 years | |
Luisa Salter-Cid | M | 60 | 13 years | |
Elizabeth Mily | F | 56 | - | |
Anup Marda | M | 46 | 18 years | |
Joseph Eid | M | 56 | 4 years | |
Vicki Goodman | M | 55 | 5 years | |
Steve Innaimo | M | - | 23 years | |
Timothy Sinclair | M | 60 | 1 years | |
Rebecca Drain | F | 61 | 3 years | |
Anthony P Waclawski | M | 62 | 6 years | |
Jill Andersen | F | - | 4 years | |
JC Xu | M | 60 | 3 years | |
Susan Sweeney | F | - | 24 years | |
Vishwas Seshadri | M | 48 | 1 years | |
Ann Lee | M | 62 | 2 years | |
George Golumbeski | M | 67 |
EMD Pharmaceuticals, Inc.
EMD Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Part of Merck KGaA, EMD Pharmaceuticals, Inc. is a private company that manufactures pharmaceutical preparations. The company is based in Durham, NC. The company was founded by Nancy J. Wysenski. | 1 years |
John H. Lawrence | M | - | 18 years | |
Matt Roden | M | 53 | 4 years | |
Kristen Hege | M | 60 | - | |
David Smoller | M | 60 | 2 years | |
Joseph C. Caldarella | M | 68 | 20 years | |
Francis Cuss | M | 69 | 14 years | |
Samuel Moed | M | 62 | 32 years | |
Irwin Scher | M | 84 | 3 years | |
David S. McCullough | M | 59 | 5 years | |
Hans-Joachim Lohrisch | M | 75 | 21 years | |
Hans-Joachim Langmann | M | - | 39 years | |
Kathryn Metcalfe | F | - | - | |
Lynne Sullivan | F | 58 | 8 years | |
Katrin Rupalla | M | 56 | 7 years | |
Anil Kapur | M | 54 | 2 years | |
Thomas Lander | M | 71 | - | |
Thomas Kuhn | M | 50 | - | |
Ken Dominski | M | - | - | |
Uta Kemmerich-Keil | F | 58 | 19 years | |
Suketu Upadhyay | M | 55 | 3 years | |
Julie Hambleton | M | 66 | 1 years | |
Murdo Gordon | M | - | 29 years | |
Malte Peters | M | 61 | 1 years | |
Kenzie Maclsaac | M | - | 4 years |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 65 | 65.00% |
Ireland | 22 | 22.00% |
Germany | 13 | 13.00% |
United Kingdom | 10 | 10.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Matthew Emmens
- Personal Network